ClinicalTrials.gg
Enrolling by invitationNCT07352384NeuroFaceUpdated Feb 20, 2026

Evaluation of the Efficacy of Neuromodulation in the Control of Chronic Orofacial Pain

An interventional study of Active Neuromodulation (tDCS or TMS) and Sham Neuromodulation (tDCS or TMS) in Orofacial Pain, sponsored by Egas Moniz - Cooperativa de Ensino Superior, CRL. Enrolling by invitation at 1 site in Portugal. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-02-20.

Sponsored by Egas Moniz - Cooperativa de Ensino Superior, CRL · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by May 2026, 6 months ago, but the record still lists the study as enrolling by invitation.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

Chronic orofacial pain significantly affects patients' quality of life, compromising essential functions such as chewing and speech. Although conventional treatments are available, many patients do not achieve adequate and lasting relief. This project investigates the effectiveness of neuromodulation techniques, namely transcranial direct current stimulation (tDCS) and transcranial magnetic stimulation (TMS), as innovative therapeutic alternatives for the control of chronic orofacial pain.

The study will be conducted in adult patients diagnosed with orofacial pain. Participants will be divided into two groups: one group will receive active neuromodulation (tDCS or TMS) and the other a sham treatment (placebo). Sessions will take place daily over two weeks. Assessments will include pain intensity, pain pressure threshold, masticatory function, and bite strength, in order to observe any functional changes.

The group undergoing neuromodulation is expected to show a significant reduction in pain levels and improvements in quality of life compared to the placebo group. This study could support the adoption of neuromodulation as a complementary approach in the treatment of chronic orofacial pain, offering an effective and non-invasive alternative for patients who do not respond to conventional treatments.

Read the detailed description

The study will be conducted at the University Clinic of the Egas Moniz School of Health and Science - Department of Orofacial Pain. The objective is to evaluate the effects of electrical and magnetic neuromodulation on different chronic pain conditions using standardized non-invasive brain stimulation protocols and validated clinical and functional assessment instruments.

Sample

Individuals with chronic low back pain (score between 40 and 80 on the Portuguese version of the Oswestry Disability Index) and chronic orofacial pain (score between 40 and 80 on the Portuguese version of the Manchester Orofacial Pain Disability Scale) will be selected.

For each chronic pain condition, 50 individuals will be enrolled and allocated into two groups: a control group and an intervention group.

Inclusion Criteria

Age between 18 and 75 years.

Diagnosis of chronic orofacial pain lasting longer than 3 months, confirmed by validated diagnostic criteria such as DC/TMD.

Initial Visual Analogue Scale (VAS) score ≥ 4.

Previous attempt of at least one conventional treatment with limited effectiveness.

Cognitive capacity sufficient to understand study procedures and provide informed consent.

Stable chronic pain medication regimen for at least four weeks prior to the intervention.

Exclusion Criteria

History of epilepsy, seizures, or other neurological conditions that contraindicate tDCS or TMS.

Presence of implanted medical devices, including pacemakers, cochlear implants, or other electronic/metallic devices in the head or neck region.

Pregnancy or breastfeeding.

Severe psychiatric disorders that may compromise adherence to study procedures.

Current or recent history (within the last six months) of alcohol or substance abuse.

Active infections or untreated systemic diseases that may interfere with the intervention or outcomes.

History of temporomandibular joint surgery or recent invasive dental procedures (within the last three months).

Known contraindications to TMS or tDCS, including intolerance to neuromodulation.

Participation in another clinical trial within the last three months.

Randomization

Participants will be randomly allocated to the control or intervention group by an independent investigator using an electronic randomization tool (Research Randomizer). Allocation will remain concealed until completion of assessments.

Sample Size Calculation

Sample size estimation indicates the need for 15 participants per group to ensure a statistical power of 85% (β = 0.20) and a significance level of p \< 0.05. The final sample size was expanded to enhance the robustness of statistical analyses and to compensate for potential dropouts.

Assessment Instruments Visual Analogue Scale (VAS)

A 0-10 numerical scale used to quantify pain intensity, where 0 indicates no pain and 10 represents the worst imaginable pain.

Brief Pain Inventory (BPI)

A multidimensional tool that assesses pain intensity and pain interference with daily activities over the past 24 hours.

Graded Chronic Pain Scale (GCPS)

A scale that classifies chronic pain into severity grades based on pain intensity and functional disability.

SF-36 Health Survey

A generic quality-of-life questionnaire comprising 36 items distributed across eight domains, with scores ranging from 0 (worst health status) to 100 (best health status).

Manchester Orofacial Pain Disability Scale

An instrument that measures functional disability associated with orofacial pain, focusing on daily activities such as chewing and speaking.

Pressure Pain Threshold (PPT)

Assessed using a portable algometer. The minimum pressure that elicits a painful sensation will be recorded. Each site will be measured twice, and the mean value will be used for analysis.

Intervention Transcranial Direct Current Stimulation (tDCS)

tDCS will be administered using 35 cm² electrodes for 20 minutes across five consecutive days. The anode will be positioned at C3 or C4, contralateral to the primary site of pain, according to the international 10-20 EEG system. The control group will receive sham stimulation with identical electrode placement and procedures.

Transcranial Magnetic Stimulation (TMS)

TMS will be delivered in 10 sessions over two weeks. The intervention group will receive active stimulation, while the control group will receive sham stimulation. Stimulation parameters (frequency, intensity, and coil placement) will follow standardized clinical research guidelines for chronic pain.

02

Conditions studied

  • Orofacial Pain

Keywords

  • Transcranial Magnetic Stimulation (TMS)
  • Transcranial Direct Current Stimulation (tDCS)
  • Neuromodulation
  • Orofacial Pain
  • Chronic Pain
03

In context

Facial Pain

183 studies on the registry are indexed under Facial Pain; 62 are open to participants now.

This study's planned enrollment of 50 is close to the median of 50 across 133 interventional studies indexed under Facial Pain.

Browse Facial Pain studies →

Lead sponsor

Egas Moniz - Cooperativa de Ensino Superior, CRL is the lead sponsor of 41 studies on the registry; 16 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age: Participants between 18 and 75 years old.
  • Diagnosis of Chronic Orofacial Pain: Patients with persistent orofacial pain for more than 3 months, confirmed using DC/TMD or other validated diagnostic criteria.
  • Pain Intensity: Baseline score on the Visual Analogue Scale (VAS) ≥ 4 (moderate to severe pain).
  • Treatment History: Patients who have previously tried at least one conventional treatment (e.g., medication or physiotherapy) with limited or no success.
  • Cognitive Ability: Participants cognitively able to understand the study procedures and provide .
  • Stable Medication Regimen: Stable chronic pain medication for at least four weeks prior to the intervention.

Exclusion criteria

Exclusion Criteria:

  • Neurological Disorders: History of epilepsy, seizures, or other neurological disorders that contraindicate TMS or tDCS.
  • Implanted Medical Devices: Presence of pacemakers, cochlear implants, or other electronic/metallic devices in the head or neck region.
  • Pregnancy: Pregnant or breastfeeding individuals, due to potential risks.
  • Psychiatric Disorders: Severe psychiatric disorders (e.g., schizophrenia, unstable major depression) that may interfere with study adherence.
  • Substance Abuse: Current or recent history (within the last 6 months) of alcohol or substance abuse.
  • Active Medical Conditions: Active infections or untreated systemic diseases that may interfere with results.
  • TMJ Surgery: History of recent temporomandibular joint surgery or invasive dental procedures (within the last 3 months).
  • for TMS/tDCS: Sensitivity, intolerance, or inability to tolerate the neuromodulation device.
  • Participation in Another Study: Simultaneous or recent (within the last 3 months) participation in another clinical trial.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
50 participants (estimated)

Study arms

  • Active comparator
    Active Neuromodulation

    Participants assigned to this arm receive active neuromodulation using either transcranial direct current stimulation (tDCS) or transcranial magnetic stimulation (TMS), according to the study protocol. Stimulation parameters follow standardized therapeutic settings, including electrode/coil placement, intensity, and session duration. The intervention is delivered over a 2-week schedule. Active stimulation is designed to modulate cortical excitability and pain-related neural circuits.

    Device: Active Neuromodulation (tDCS or TMS)

  • Placebo comparator
    Sham/Placebo Neuromodulation

    Participants in this arm receive sham (placebo) neuromodulation designed to mimic the sensory experience of tDCS or TMS without delivering effective stimulation. For tDCS, the device provides brief ramp-up/ramp-down current; for TMS, a sham coil or tilted coil reproduces sound and scalp sensation without inducing cortical effects. Procedures, duration, and interactions are identical to the active arm to maintain blinding.

    Device: Sham Neuromodulation (tDCS or TMS)

Interventions

  • DeviceActive Neuromodulation (tDCS or TMS)

    Participants receive active non-invasive neuromodulation using either transcranial direct current stimulation (tDCS) or transcranial magnetic stimulation (TMS). For tDCS, stimulation is delivered with 35 cm² electrodes, 1-2 mA, for 20 minutes, with the anode placed over C3 or C4 contralateral to the pain side, for five consecutive sessions. For TMS, stimulation is delivered with a figure-of-eight coil targeting the motor cortex corresponding to the orofacial region, following established safety protocols (e.g., 10 sessions across two weeks). All procedures follow standardized therapeutic parameters aiming to modulate cortical excitability and reduce pain.

    Also known as: Active tDCS, Active TMS, Active neuromodulation therapy

  • DeviceSham Neuromodulation (tDCS or TMS)

    Participants receive sham stimulation designed to mimic the sensory experience of tDCS or TMS without producing physiological neuromodulatory effects. For tDCS, the device uses brief ramp-up/ramp-down currents to simulate tingling without active stimulation. For TMS, a sham coil or angled coil is used to reproduce acoustic and scalp sensations while preventing magnetic induction. Session duration, procedures, and interaction with the operator are identical to the active arm to maintain blinding integrity.

    Also known as: Sham tDCS, Sham TMS, Placebo neuromodulation

06

What researchers measure

Primary outcomes

  1. Pain Intensity Assessed by Visual Analogue Scale (VAS)

    Pain intensity will be assessed using a 10-cm Visual Analogue Scale (VAS), in which participants rate their average pain intensity by marking a point on a horizontal line anchored by "no pain" (0) and "worst pain imaginable" (10). Higher scores indicate greater pain intensity.

    Time frame: Baseline, at the end of the 2-week intervention period (after 10 sessions), and 1 month after completion of the intervention

Secondary outcomes

  1. Pain Interference Measured by the Brief Pain Inventory (BPI)

    Pain-related interference will be evaluated using the interference subscale of the Brief Pain Inventory (BPI). The BPI assesses the extent to which pain interferes with daily activities, including general activity, mood, walking ability, work, relationships, sleep, and enjoyment of life. Each item is rated on a 0-10 numeric scale, with higher scores indicating greater interference.

    Time frame: Baseline, at the end of the 2-week intervention period (after 10 sessions), and 1 month after completion of the intervention

  2. Chronic Pain Severity Assessed by the Graded Chronic Pain Scale (GCPS)

    Chronic pain severity will be assessed using the Graded Chronic Pain Scale (GCPS), which classifies pain according to pain intensity and pain-related disability. The GCPS generates grades ranging from Grade 0 (no pain) to Grade IV (high disability-severely limiting), with higher grades indicating greater pain-related impairment.

    Time frame: Baseline, at the end of the 2-week intervention period (after 10 sessions), and 1 month after completion of the intervention

  3. Health-Related Quality of Life Measured by SF-36

    Health-related quality of life will be assessed using the 36-Item Short Form Health Survey (SF-36), which evaluates eight domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. Scores for each domain range from 0 to 100, with higher scores indicating better perceived health status.

    Time frame: Baseline, at the end of the 2-week intervention period (after 10 sessions), and 1 month after completion of the intervention

  4. Pressure Pain Threshold (PPT)

    Pressure pain threshold will be measured using a pressure algometer applied to predefined orofacial and/or cervical muscle sites. PPT is defined as the minimum pressure (expressed in kPa or kg/cm²) at which pressure sensation becomes painful. Higher PPT values indicate lower pain sensitivity.

    Time frame: Baseline, at the end of the 2-week intervention period (after 10 sessions), and 1 month after completion of the intervention

  5. Orofacial Functional Disability Assessed by the Manchester Orofacial Pain Disability Scale (MOPDS)

    Orofacial functional disability will be evaluated using the Manchester Orofacial Pain Disability Scale (MOPDS), a self-reported questionnaire that assesses the impact of orofacial pain on daily functional activities. Higher scores reflect greater levels of functional disability related to orofacial pain.

    Time frame: Baseline, at the end of the 2-week intervention period (after 10 sessions), and 1 month after completion of the intervention

07

Study locations

1 site
08

References and documents

Publications

  • Fricova J, Englerova K, Rokyta R. Noninvasive transcranial direct current stimulation (tDCS) for the treatment of orofacial pain. Neuro Endocrinol Lett. 2016 Oct;37(5):368-372. PubMed 28231681 ↗
  • Fricova J, Rokyta R. Transcranial Neurostimulation (rTMS, tDCS) in the Treatment of Chronic Orofacial Pain. Prog Neurol Surg. 2020;35:125-132. doi: 10.1159/000511134. Epub 2020 Oct 12. PubMed 33045706 ↗
  • Mayor RS, Ferreira NR, Lanzaro C, Castelo-Branco M, Valentim A, Donato H, Lapa T. Noninvasive transcranial brain stimulation in central post-stroke pain: A systematic review. Scand J Pain. 2024 Jul 3;24(1). doi: 10.1515/sjpain-2023-0130. eCollection 2024 Jan 1. PubMed 38956966 ↗
  • Ferreira NR, Junqueira YN, Correa NB, Fonseca EO, Brito NBM, Menezes TA, Magini M, Fidalgo TKS, Ferreira DMTP, de Lima RL, Carvalho AC, DosSantos MF. The efficacy of transcranial direct current stimulation and transcranial magnetic stimulation for chronic orofacial pain: A systematic review. PLoS One. 2019 Aug 15;14(8):e0221110. doi: 10.1371/journal.pone.0221110. eCollection 2019. PubMed 31415654 ↗
  • Herrero Babiloni A, Guay S, Nixdorf DR, de Beaumont L, Lavigne G. Non-invasive brain stimulation in chronic orofacial pain: a systematic review. J Pain Res. 2018 Aug 1;11:1445-1457. doi: 10.2147/JPR.S168705. eCollection 2018. PubMed 30122975 ↗
  • Knotkova H, Hamani C, Sivanesan E, Le Beuffe MFE, Moon JY, Cohen SP, Huntoon MA. Neuromodulation for chronic pain. Lancet. 2021 May 29;397(10289):2111-2124. doi: 10.1016/S0140-6736(21)00794-7. PubMed 34062145 ↗

Individual participant data

Plan to share: No — Individual Participant Data (IPD) from this study will not be shared with other researchers. Rationale for Non-Sharing: Informed Consent Limitations: The current informed consent forms signed by participants do not explicitly authorize the future public sharing or distribution of individual raw data, which limits our ability to comply with broad data sharing requests while maintaining ethical compliance. Data Sensitivity and Privacy: The collected data involves sensitive clinical information regarding chronic pain and psychiatric history. Although data is anonymized, the potential for re-identification, especially within small subgroups defined by specific conditions (e.g., both chronic orofacial pain and specific comorbidities), necessitates a conservative approach to protect participant privacy. Study Specificity: The complex, multi-modal intervention (TMS/tDCS) and assessment protocols used are highly specific to the research team's infrastructure and methodology, making the data

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for May 2026, 6 months after the start.

Of 55 non-industry interventional studies with no phase under Facial Pain, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 34. This study's planned 6 months is below that.

Counting every sponsor, half of 59 studies reached it within 17 months; a quarter within 8 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2025
First posted
Jan 20, 2026
StartActual
Nov 1, 2025
Primary completionEst.
May 1, 2026
CompletionEst.
Aug 1, 2026
Last update
Feb 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07352384
Lead sponsor
Egas Moniz - Cooperativa de Ensino Superior, CRL
Collaborators
University of Sao Paulo, University of Aarhus, Universidade Federal de Alfenas
Responsible party
Sponsor
First posted
Jan 20, 2026
Start date
Nov 1, 2025
Primary completion
May 1, 2026 (estimated)
Completion
Aug 1, 2026 (estimated)
Last update
Feb 20, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion